• Da-Yin Chen, Liang Cheng, Long-Xin Dong, Wen-Jie He, Hui-Feng Cao, Ping Wang, and Cai-Fang Yue.
• Department of Urology.
• Medicine (Baltimore). 2020 Jun 5; 99 (23): e20415.

BackgroundThis study will aim to appraise the efficacy and safety of pirarubicin for the treatment of patients with nonmuscle invasive bladder cancer (NMIBC).MethodsWe will perform a comprehensive literature search in MEDLINE, EMBASE, Cochrane Library, Scopus, PsycINFO, Web of Science, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure from their beginning to the February 29, 2020. All randomized controlled trials of pirarubicin for NMIBC will be included regardless limitations related to the language and publication time. Two researchers will independently select studies from searched records, extract data from included randomized controlled trials, and assess study quality using Cochrane risk of bias tool. Any differences between them will be solved with the help of another researcher. RevMan 5.3 software will be utilized for statistical analysis.ResultsThis study will provide a synthesis of current evidence to investigate the efficacy and safety of pirarubicin for NMIBC using overall survival, progression-free survival, recurrence-free survival, quality of, rates of recurrence, and adverse events.ConclusionThis study will explore whether or not pirarubicin can be used as an effective and safety treatment for patients with NMIBC.Registration NumberINPLASY202040113.

11 keywords...

hide…